RCS - Genflow Biosciences - Update on the Dog Study

Genflow BiosciencesAnnouncement

Wed 09:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260408:nRSH6270Za&default-theme=true

RNS Number : 6270Z  Genflow Biosciences PLC  08 April 2026

 

8 April 2026

 

Genflow Biosciences Plc

 

Genflow Reports Sustained Safety and Efficacy Three Months Post Dosing in SLAB
Trial

 

Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the
"Company"), a European-based biotechnology company focused on the development
of gene therapies for age-related diseases, highlights continued positive
safety and efficacy signals from its ongoing SLAB (Sarcopenia and Longevity in
Aged Beagles) clinical trial evaluating its proprietary SIRT6 centenarian gene
therapy.

 

Follow-up observations conducted three months after the initial dosing period
confirm that previously reported improvements have been maintained. No adverse
events have been observed, and the therapy continues to demonstrate a
favourable safety and tolerability profile in aged dogs.

 

These findings build on the Company's previously announced interim results
(please see the Company's announcement dated 12 February 2026 here
(https://www.londonstockexchange.com/news-article/GENF/preliminary-interim-results-from-dog-study/17457646)
) and provide early evidence supporting the durability of the therapy's
effects. Improvements across multiple independent endpoints remain consistent
with earlier observations, while control animals continue to exhibit expected
age-related decline.

 

The SLAB study remains ongoing, with all dogs continuing to be actively
monitored and evaluated. The trial is expected to continue for a further four
months, with completion anticipated at the end of July 2026. Additional
analyses, including methylation clock (biological age) assessment and muscle
histology, are in progress and are expected to provide further mechanistic and
quantitative insight into the therapy's impact.

 

Dr Eric Leire, Chief Executive Officer of Genflow said: "These follow-up
observations are important as they extend our understanding beyond initial
efficacy and into persistence of effect. The consistency of improvements
across multiple functional endpoints, together with the continued absence of
safety concerns, strengthens our confidence that SIRT6 gene therapy is
delivering a sustained biological impact.

 

Based on the data observed to date, we believe this supports the positioning
of our SIRT6 platform as a potentially disease-modifying approach to
addressing age-related decline in companion animals. As the study progresses,
we continue to engage with prospective partners across animal health to
explore licensing, co-development, and commercialisation opportunities."

 

Further updates will be provided as additional data becomes available.

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32 477495 881       +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies for age-related diseases, with the goal
of promoting longer and healthier lives while mitigating the financial,
emotional, and social impacts of a fast-growing aging global population.
Genflow's lead compound, GF-1002, works through the delivery of a centenarian
variant of the SIRT6 gene which has yielded promising preclinical results.
Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian
gene therapy in aged dogs began in March 2025. Other programs include a
clinical trial that will explore the potential benefits of GF-1002 in treating
MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent
chronic liver disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

 

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

 

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

 

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAAKFBPOBKKDQK



            Copyright 2019 Regulatory News Service, all rights reserved